Isolation and Characterization of a Novel Myophage Abp9 Against Pandrug Resistant Acinetobacater baumannii

Lingli Jiang†, Jingjie Tan†, Yi Hao†, Qi Wang†, Xiaorui Yan‡, Dali Wang†, Li Tuo‡*, Zairong Wei‡* and Guangtao Huang‡*

†Department of Burn and Plastic, Affiliated Hospital of Zunyi Medical University, Zunyi, China, ‡Life Sciences Institute, Zunyi Medical University, Zunyi, China

Acinetobacter baumannii (A. baumannii) has emerged as one of the most troublesome pathogens in health care institutions. A. baumannii can cause a wide range of diseases in humans, including pneumonia and septicemia. Phage therapy has drawn great interest from medical researchers as a potential way to control infections by antibiotic-resistant A. baumannii. Using a pandrug-resistant clinical A. baumannii isolate AB279 as an indicator, we isolated a lytic phage Abp9 from hospital sewage. Abp9 belongs to myoviridae family and shows a wider host range of 12%. Abp9 contains a linear double-stranded DNA genome of 44,820 bp with a G+C content of 37.69%. The Abp9 genome contains 80 open reading frames, but lacks any known virulence genes or lysogen-formation genes. In a systemic A. baumannii infection mouse models, Abp9 treatment showed good therapeutic effects. We have also observed an excellent lytic activity against A. baumannii in biofilm form of growth in vitro. All of these suggest that Abp9 is a good candidate for the phage therapy against drug-resistant A. baumannii infections.

Keywords: Acinetobacter baumannii, phage therapy, biofilm, pandrug resistance, cell lysis

INTRODUCTION

A. baumannii is an aerobic bacillus of non-fermentative, Gram-negative bacteria. A. baumannii usually inhabits in soil, sewage, surface of medical appliances and hospital environments, from where it can cause bacteremia, pneumonia, cephalemoningitis and infections of urinary tract, skin and soft tissues, especially under immunosuppressive status (Maragakis and Perl, 2008; Peleg et al., 2008; Freire et al., 2016; Gong et al., 2016).

A. baumannii is one of the leading pathogens causing hospital infection (Hauck et al., 2012; Bahador et al., 2015; Gong et al., 2016; Huang et al., 2016). In recent years, increasing attention was paid to A. baumannii as its ability to quickly develop antibiotic resistance. This adaption is mainly attributed though its plastic genome, which rapidly mutates when facing adversity and stress. A. baumannii could also form robust biofilm with in the wound and on occlusive dressings, as well as on most abiotic surfaces. These characteristics make it difficult to eliminated A. baumannii completely. World Health Organization has declared A. baumannii as one of the most serious ESKAPE organisms (Pereira et al., 2018). Meanwhile,
the Centers for Disease Control and Prevention (CDC) categorized multidrug resistance (MDR) A. baumannii as a serious threat.

Phage therapy is a promising therapeutic method that could be deployed against the global superbug crisis. PhagoBurn was the first randomized controlled trial to investigate phage therapy which was launched in June 2013 and ended in February 2017 (Jault et al., 2019). Over the past few years, a growing number of researchers have focused on isolating and validating the use of phages for therapy and prophylaxis in the war against drug-resistant A. baumannii. Currently, 21 A. baumannii phages have been sequenced and released in databases. AP22, was the first reported A. baumannii genome bioinformatic analysis of the phage of myoviridae family (Popova et al., 2012). A detailed genome bioinformatic analysis of the A. baumannii phage AB1 was also reported in 2012 (Li et al., 2012). The therapeutic efficacy of phage therapy against carbapenem-resistant A. baumannii (CRAB) infections in Galleria mellonella larvae and a mouse model of acute pneumonia had been reported (Jeon et al., 2019). In our previous study, phage Abp1 could rescue mice from Pandrug Resistant A. baumannii infections (Yin et al., 2017). Meanwhile, on-demand phage isolation has also showed promising results (Mattila et al., 2015). Even more, personalized bacteriophage-based therapeutic cocktails was also used in necrotizing pancreatitis caused by MDR A. baumannii (Schooley et al., 2017). Combination of bacteriophages and antibiotics had also been reported to save a patient’s leg with trauma-related left tibial A. baumannii infection (Nir-Paz et al., 2019). So far, none clinical trial on A. baumannii phages is reported (PubMed and web of science) or registered.

We recently isolated A. baumannii strain ABZY9 from the femoral vein catheter of a patient. ABZY9 is sensitive to polymyxin and resistant to aminoglycosides, carbapenems, cephalosporins, tetracyclines, and quinolones. Along with its pandrug-resistant phenotype, ABZY9 can also form biofilms in plates. We then sought to isolate a lytic bacteriophage for ABZY9 from hospital sewage. The present study reports on the successful isolation of a lytic phage we have called Abp9, which has a wide host range. After biological characterization and genome dissection, we found that Abp9 effectively cleared ABZY9-produced biofilms, and reduced the mortality of rats infected with this bacterium.

**MATERIALS AND METHODS**

**Bacterial Strains**

A. baumannii strain ABZY9 was isolated from a burn patient. After identified by VITEK, ABZY-9 was further confirmed as A. baumannii species by MLST analysis and 16S rRNA sequencing (27S5′-AGATTGATGCTGCTCAG-3′, 1492r:5′-GGTTACCTTGTTACGACT T-3′) (Huang et al., 2013). For MLST analysis, seven conserved genes (gltA, gyrB, gdhB, recA, cprn60, gpi, and rpoD) were sequenced (Huang et al., 2016).

**Bacteriophage Isolation and Transmission Electron Microscopy (TEM)**

Abp9 was isolated from sewage using ABZY9 as the host bacterium with previous method (Huang et al., 2013). Briefly, a total of 1 L filtered hospital sewage was incubated overnight with 100 mL ABZY9 (OD600 around 1.0). The supernatant was collected and tested for phages with a double-layer plate. The plaques can be observed after incubation at 37°C overnight. The phage particles were prepared by CsCl gradient ultracentrifugation (Nasukawa et al., 2017). CsCl-purified Abp9, at a concentration of 1011 PFU/mL, was deposited onto carbon-coated copper grids and allowed to adsorb for 15 min. The phage particles were negatively stained using 2% (w/v) potassium phosphotungstate and visualized with a transmission electron microscope. The length and width of Abp9 was measured with ImageJ. Phage DNA was isolated using a phage genome kit (Norgen, Canada).

**One-Step Growth Assay**

For one-step growth experiments, a previous described method was used. Briefly, after phage adsorption at room temperature for a 15 min, centrifugation at 13,000 g for 30 s, followed by removing the supernatant. The pelleted cells were resuspended in 5 mL of preheated (37°C) LB broth and incubated at 37°C. Samples were taken at 10 min intervals. Phage titers were immediately obtained. Experiments were repeated at least three times with duplicate samples.

**Host-Range Determination**

For host-range test, a total of 97 (ABZY9 not included) clinical A. baumannii isolates were tested with a previous described method. These 97 clinical isolates were collected in our previous study (Huang et al., 2016). These clinical isolates belong to 10 different STs and most of them (94/97) are MDR A. baumannii isolates. Briefly, a total of 200 µL of A. baumannii cells (OD600 around 1.0) was mixed with 3 mL of melted 0.6% agar (50°C), and this mixture was poured onto 1.5% solid agar to make double-layer agar plates. After solidification for 10 min, 5 µL of 108 PFU/mL of Abp9 phages was spotted onto the double-layered agar plates. After 12 h incubation, we observe whether any lysis plaques had emerged.

**Genome Sequencing**

Sequencing libraries Were generated using the TruSeq DNA Sample Preparation Kit (Illumina, United States) and the Template Prep Kit (Pacific Biosciences, United States). Genome sequencing Was performed by the Personal Biotechnology Company (Shanghai, China) on the Pacific Biosciences platform and the Illumina Miseq platform. Data assembly Was conducted using SPAdes (Bankevich et al., 2012) and A5-miseq (Coil et al., 2015) to construct the scaffolds and contigs. Canu software (Koren et al., 2017) was used to assemble the data obtained From PacBio platform sequencing. Subsequently, all assembled results Were integrated to generate a complete sequence.
Bioinformatic Analysis
Open reading frames (ORFs) were predicted using GeneMark (version 4.32). The functions of the proteins encoded by each ORF were predicted using the BLASTp database. Gene prediction was performed by Glimmer 3.02 (Delcher et al., 1999). tRNAscan-SE (Lowe and Eddy, 1997), Rfam (Lagesen et al., 2007), and Pfam (Burge et al., 2013) were used to find transfer RNA, ribosomal RNA and other non-coding RNAs, respectively. The whole genome was submitted to https://www.ncbi.nlm.nih.gov/genbank/ (NCBI accession number: MN166083). For the phylogenetic analysis, a phylogenetic tree was constructed with the Molecular Evolutionary Genetic Analysis (MEGA version 7.0) package based on a comparison of whole genome sequences.

Thermal and pH Stability of Abp9
To test the thermal stability of Abp9, a 1.5 mL volume of phages (5 × 1010 142 PFU/mL) was incubated for 15 min at 20, 30, 40, 50, 60, and 70°C, after which 100 µL aliquots were withdrawn to calculate the phage concentrations. After 10-fold dilution, 10 µL of each diluted sample was separately combined with 200 µL of host bacteria, the solutions incubated for 15 min, mixed with 3 mL of 0.75% LB agar, and then poured onto solid-agar plate of host bacteria, the solutions incubated for 15 min, mixed with 3 mL of 0.75% LB agar, and then poured onto solid-agar plate to determine the phage titers. For the pH stability assay, aliquots were collected 30 min after incubation in liquid media ranging from pH 3.0 to 12.0.

Phage Therapy in a Systemic Infection Model
A total of 36 nine-week-old SD mouse (20–30 g) were randomly divided into 3 groups. The mouse were anesthetized with continuous inhalation of isoflurane. 200 µL of PBS containing 5.0 × 10⁷ CFU ABZY9 cells was injected intraperitoneally into the mice. Immediately after infection, phage (5.0 × 10⁶ PFU) in PBS were injected intraperitoneally on the same side of the mouse used for the bacterial injection. Phage were injected again after 12 h. The animals were monitored for 7 days and the survival rate of each group was calculated.

Biofilm Removal Ability of Abp9
A. baumannii biofilm formation assays were conducted as described previously (O’Toole and Kolter, 1998). Briefly, 100 µL of an overnight A. baumannii culture was 5 mL of fresh LB medium. After 2–3 h, the cells were harvested when the OD600 reached 1.0 (around 5 × 10⁸ CFU/mL). After diluting the medium 50 times, 100 µL of culture (around 1 × 10⁷ CFU/mL) was added to each well of a 96-well plate (Beaver, China), and the plate was incubated at 37°C for 24 h. A 10 µL aliquot (1 × 10⁸ PFU) of phage lysate was added to each well in the phage treatment group. In the control group, the same volume of TM buffer (10 mM Tris-HCl, pH 8.0/10 mM MgSO4) was added. Non-attached bacteria were removed by tapping out and rinsing the wells three to four times by immersing the plates into a tub of water, then pouring the water out of the wells. After formaldehyde fixation, crystal violet was used for biofilm staining. The stained dye was washed out with 95% ethanol and subjected to OD595 measurement using a micro plate reader.

Ethics Statement
All animal experiments were complied with the International Guiding Principles for Biomedical Research involving Animals (1985) and were approved by the Laboratory Animal Welfare and Ethics Committee of Zunyi Medical University. The approval number for the animal experiment is 2019-2-032.

Statistical Analysis
Data were analyzed by one-way analysis of variance (ANOVA) or log-rank test (Mantel-Cox) as appropriate. A value of P < 0.05 was considered significant.

RESULTS
Abp9 Is a Lytic Myophage Phage
When the OD600 of ABZY9 culture reached to 1.0, a total of 10 µL (5 × 10⁷ PFU) Abp9 were added into the culture. Three hours later, the ABZY9 culture become almost clear and bacterial residue settles to the bottom (Figures 1A,B). As shown in Figure 1C, OD600 of ABZY9 dropped quickly in phage group. The OD600 decreased to almost zero 6 h after adding phage. Meanwhile, the viable bacterial counts of A. baumannii ABZY9 decreased from 5.4 × 10⁸ CFU/mL to 4.5 × 10⁶ CFU/mL.

After incubation for 8 h at 37°C, Abp9 formed clear plaques on the double-layered plate (Figure 2A). The plaques were clear with diameters of around 1–3 mm, and semi-transparent halos were apparent on the host’s bacterial lawns (Figure 2A). As Figure 2B shows, Abp9 is a Myoviridae family member. Abp9 has an icosahedral head (as seen by the simultaneous presence of hexagonal and pentagonal capsids) of 55.3 ± 2.2 nm in diameter. The head is separated from the tail sheath by a 16.4 ± 4.1 nm long neck. Abp9 possess a contractible tail measuring (101.7 ± 4.0) × (17.9 ± 1.2) nm. As shown in Figure 2C, after a latent 30 min phase, Abp9 burst out of the cells 40 min after their infection. The burst size of the phage was approximately158 PFU/cell.

Phage Stability
As shown in Figure 3A, Abp9 also exhibits good pH stability. Abp9 survival was high from pH 7.0 to 11.0. Abp9 titers decreased significantly between pH 3.0 and 6.0, and from 11.0 to 12.0. Abp9 is also relatively thermal-stable at 50°C (Figure 3B). No difference of phage titers were detected at 20, 30, 40, and 50°C. However, phage titers decreased around 10-folds after incubation at 60°C for 15 min. No more than 1% of phage were viable after 15 min incubation at 70°C. These results demonstrate that Abp9 retains activity well above 37°C, which simplifies its storage and delivery. The broad range of thermal and pH stability facilitates the application of Abp9 in phage therapy.

Footnote:
1http://topaz.gatech.edu/GeneMark/
2https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins
General Features of the Abp9 Genome

The entire Abp9 genome was sequenced. After quality control, 5,208,458 reads and 27,585 genome coverage were obtained. The final genome assembly yielded a 44,820 bp linear, dsDNA molecule with 37.69% G+C content. A total of 80 ORFs larger than 100 bp were identified using ORF Finder. ORF density is around 1.8 genes per kb. The average length of a gene was approximately 487 bp.

As shown in Supplementary Table 1, genome annotation of Abp9 was listed. Sixty seven genes were encoded on the positive strand and 13 genes on the negative strand. Of these 80 gens, only 16 genes were function-known after bioinformatic analysis. Five structural proteins were identified, including head protein, base plate protein and tail protein. DNA helicase, endodeoxyribonuclease, and two terminase subunits were identified. Some regulatory genes were also identified in Abp9, including antirepressor protein, superinfection immunity protein, transcriptional dual regulator, secretion activator protein and superinfection immunity protein. Figure 4A shows the genome map of Abp9. The genome sequence was deposited in the NCBI genome database under GenBank accession number MN166083.

Genome-Wide Comparison

A total of 21 sequenced A. baumannii phage genomes were downloaded and compared with Abp9. Most of these 21 genomes fall into two major groups. As shown in Figure 4B, Abp9 shares the highest similarity with Acinetobacter phage WCHABP12 (NC_041924.1), a Chinese isolate, followed by A. bacteriophage AP22 (HE806280.1), a Russian isolate. The query coverage for WCHABP12 and AP22 was 85 and 64%, respectively. In contrast, Abp9 was found to share least similarity with Acinetobacter phage phiAC-1 (JX560521.1).

Host Range and Phage Therapy in a Systemic Infection Model

We subjected 97 clinical isolates of A. baumannii clinic strains and found 12 of them were sensitive to Abp9. Only one of the 12 phage-sensitive clinic isolates are antibiotic-sensitive strain and others are MDR strains. The 12 strains also belonged to 5 different STs (ST368 6 isolates, ST208 2 isolates, ST191 1 isolates, ST136 1 isolates, new STs 2 isolates). No shared antibiotic resistance phenotype and molecule ST types among these 12 phage-sensitive strains were identified. In addition, A. baumannii clinic strain ATCC19606, Pseudomonas aeruginosa strain PAO1 and Escherichia coli strains JM109, DH5a were also tested and all showed resistance to the Abp9. To further investigate the potential therapeutic effects of Abp9 against systemic infections, we devised an A. baumannii mouse infection model. As shown in Figure 5, infected mouse in the negative group succumbed gradually to the infection. In the no phage treatment group, the infected mouse started to die at 3 days post-infection and eight mouse survived after 1 week, suggesting that Abp9 therapy has potential clinical utility for the control of systemic infections.
In vitro Biofilm Lytic Activity of Abp9

Infections involving biofilm formation by the *A. baumannii* are very difficult to eliminate. To test the biofilm removal ability of Abp9, a biofilm model in vitro was used in this study. As shown in Figure 6, the biofilm density tested by OD$_{595}$ decreased significantly from 1.80 to 0.50 after co-cultured with phage Abp9 for 2 h. This result indicates that Abp9 could clear biofilm efficiently.

DISCUSSION

Due to the narrow host range of phages, on-demand phage isolation of specific pathogens might be a compromise strategy for phage therapy. In this study, a lytic phage was isolated from hospital sewage with the host bacteria AB$_{ZY}$9, which was isolated from the catheter of a burn patient. The morphology observed by electron microscope indicated that Abp9 belongs to *myoviridae* (Figure 2B).
FIGURE 3 | Thermal and pH stability of Abp9. (A) pH stability. Phage Abp9 was incubated at the indicated pH conditions for 30 min. Data were obtained from three independent experiments and are shown as mean ± standard deviation. (B) Thermal stability of Abp9. Phage titers start to decrease when the temperature over 50 degree. Data are presented as mean ± standard deviations from three replicates. “ns” means no significant difference, “*” means \( p < 0.05 \), “**” means \( p < 0.01 \).

FIGURE 4 | Circular genome map and genome comparison of phage Abp9. (A) The innermost circle represents GC skew (purple: GC skew–; green: GC skew+); the black circle in the middle represents the GC content (black outwards indicate GC content greater than 37.69%, and black inwards indicate the opposite); the outermost circle shows 80 predicted ORFs. (B) The phylogenetic tree was constructed with MEGA using the whole genome sequences with MEGA. A total of 21 sequenced \( A. \) baumannii phage genomes, together with SP6 and T7 phage, were aligned together with the Abp9.

Previously, several \( A. \) baumannii myophages had been reported (Lee et al., 2011; Jin et al., 2012; Essoh et al., 2019; Oliveira et al., 2019; Popova et al., 2019), including Abp53, vB_AbaM_B9, ZZ1, Aci01-1, Aci02-2, Aci05, and AM24. Abp53 has a DNA genome of 95 kb, which encodes several proteins similar to those encoded by host \( A. \) baumannii and \( K. \) phage phiKO2 reported by Lee et al. (2011). vB_AbaM_B9 has a genome of 93,641 bp and encodes 167 predicted proteins, with a G + C content of 33.6%. vB_AbaM_B9 could specifically lytic from without in strains of the K45 and K30 capsule types (Oliveira et al., 2019). AM24 also contains 167 ORFs, with 127 function-unknown genes. However, it has a linear double-stranded DNA genome of 97,177 bp, with a G + C content of 37.3% (Popova et al., 2019). ZZ1 possesses a double-stranded DNA with a total length of 166 kb. Bioinformatic analysis of the phage whole genome sequence further suggested that ZZ1 was more likely to be a new member of the \( \text{Myoviridae} \) phages (Jin et al., 2012). The Aci01-1, Aci02-2, and Aci05 genomes were 103, 104, and 102 kb long with direct terminal repeats (DTRs) of 1,184, 1,198, and 1,151 bp, respectively.
The genome size and architecture and the presence of a DTR and tRNAs suggest that these phages may be members of the Felixounavirinae subfamily (Essoh et al., 2019) Abp9 possess a relatively small genome than the other three myophages of *A. baumannii*. Abp9 contains a linear double-stranded DNA genome of 44,820 bp with 37.7% G + C content. BLASTP search predicted the functions of 16 ORFs, most of which resembled proteins of *Acinetobacter* phage WCHABP1 and *Acinetobacter* phage WCHABP12.

Abp9 shows good thermal stability from 20 to 50°C, and phage titers decreased significantly at temperatures over 60°C (Figure 3B). Thus, this level of thermal stability may facilitate the application of Abp9 in phage therapy. In rats with severe burn wound infection model, Abp9 local administration treatment showed a higher survival rate than the negative group (Supplementary Figure S1). However, there is no significant difference (p = 0.096). Based on our systemic mice infection model, Abp9 shows potential for use in controlling *A. baumannii*.
infections, which is important because this bacterium can form biofilms on the surfaces of catheters or wounds. Phage therapy is being explored as a new tool for clearing biofilms. Here, we found that Abp9 was able to remove biofilms formed by ABZY9 (Figure 6). The depolymerase activities of some phages, which degrade components of the biofilm exopolymeric matrix, enable them to infect the inner cells of biofilms (Carson et al., 2010). Thus, it is possible that the depolymerases produced by phages used in clinic as biofilm-penetrating antibiotics (Verma et al., 2010).

In the present study, we have isolated a lytic phage against a clinical A. baumannii strain ABZY-9 A. baumannii strain, which was isolated from the femoral vein catheter of a patient. Our TEM analysis indicates that Abp9 belongs to the Myoviridae bacteriophage family. Abp9 exhibits a broad range of thermal stability and can clear biofilms efficiently in vitro. Thus, Abp9 has potential for treating patients suffering A. baumannii infections.

**DATA AVAILABILITY STATEMENT**

The datasets generated for this study can be found in the NCBI (accession number MN166083).

**ETHICS STATEMENT**

The animal study was reviewed and approved by the Laboratory Animal Welfare and Ethics Committee of Zunyi Medical University.

**REFERENCES**

Bahador, A., Raoofian, R., Pourakbari, B., Taheri, M., Hashemizadeh, Z., and Hashemi, F. B. (2015). Genotypic and antimicrobial susceptibility of carbapenem-resistant Acinetobacter baumannii: analysis of is aba elements and bla OXA-23-like genes including a new variant. *Front. Microbiol.* 6:1249. doi: 10.3389/fmicb.2015.01249

Bankevich, A., Nurk, S., Antipov, D., Gurevich, A. A., Dvorkin, M., Kulikov, A. S., et al. (2012). SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *J. Comput. Biol.* 19, 455–477. doi: 10.1089/cmb.2012.0021

Burge, S. W., Daub, J., Eberhardt, R., Tate, J., Barquist, L., Nawrocki, E. P., et al. (2013). Rfam 11.0: 10 years of RNA families. *Nucleic Acids Res.* 41, D226–D232. doi: 10.1093/nar/gks1005

Carson, L., Gorman, S. P., and Gilmore, B. F. (2010). The use of lytic bacteriophages in the prevention and eradication of biofilms of *Proteus mirabilis* and *Escherichia coli*. *FEMS Immunol. Med. Microbiol.* 59, 447–455. doi: 10.1111/j.1574-695X.2010.00696.x

Coil, D., Jospin, G., and Darling, A. E. (2015). A5-miseq: an updated pipeline to assemble microbial genomes from Illumina MiSeq data. *Bioinformatics* 31, 587–589. doi: 10.1093/bioinformatics/btu661

Delcher, A. L., Harmon, D., Kasif, S., White, O., and Salzberg, S. L. (1999). Improved microbial gene identification with GLIMMER. *Nucleic Acids Res.* 27, 4636–4641. doi: 10.1093/nar/27.23.4636

Essoh, C., Vernadet, J. P., Vergnaud, G., Coulibaly, A., Kakou-N’Douba, A., N’Guetta, A. S., et al. (2019). Complete genome sequences of five *Acinetobacter baumannii* phages from abidjan, Côte d’Ivoire. *Microbiol. Resour. Announc.* 8:e01358-18. doi: 10.1128/mra.01358-18

Funding This work was supported by the National Natural Science Foundation of China (Nos. 81801916 and 81960353), Zunyi Science and Technology Cooperation (No. 2019-50), Affiliated Hospital of Zunyi Medical University Doctoral Start up Fund (2018-11), and Science and Technology Support Project of Guizhou Province (2020-4Y003 and 2020-1Y332).

**ACKNOWLEDGMENTS**

We would like thank Dr. Yizhi Peng (Army Military Medical University, China) for help of suggestions on the experiments and providing *A. baumannii* strains. We also thank Dr. Elizabeth G. Wills (Cornell University) for the help on language.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2020.506068/full#supplementary-material

**FIGURE S1 | Survival rate of Abp9 therapy in severe burn infection rat model.**
infected by *Pseudomonas aeruginosa* (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. *Lancet Infect. Dis.* 19, 35–45. doi: 10.1016/s1473-3099(18)30482-1

Jeon, J., Park, J. H., and Yong, D. (2019). Efficacy of bacteriophage treatment against carbapenem-resistant *Acinetobacter baumannii* in Galleria mellonella larvae and a mouse model of acute pneumonia. *BMC Microbiol.* 19:70. doi: 10.1186/s12866-019-1443-5

Jin, J., Li, Z. J., Wang, S. W., Wang, S. M., Huang, D. H., Li, Y. H., et al. (2012). Isolation and characterization of Z21, a novel lytic phage that infects *Acinetobacter baumannii* clinical isolates. *BMC Microbiol.* 12:156. doi: 10.1186/1471-2180-12-156

Koren, S., Walenz, B. P., Berlin, K., Miller, J. R., Bergman, N. H., and Phillippy, A. M. (2017). Canu: scalable and accurate long-read assembly via adaptive k-mer weighting and repeat separation. *Genome Res.* 27, 722–736. doi: 10.1101/ gr.215087.116

Lagesen, K., Hallin, P., Rødland, E. A., Staerfeldt, H. H., Rognes, T., and Ussery, D. W. (2007). RNAmmer: consistent and rapid annotation of ribosomal RNA genes. *Nucleic Acids Res.* 35, 3100–3108. doi: 10.1093/nar/gkm160

Lee, C. N., Tseng, T. T., Lin, J. W., Fu, Y. C., Weng, S. F., and Tseng, Y. H. (2011). Lytic myophage Abp53 encodes several proteins similar to those encoded by host *Acinetobacter baumannii* and phage phiKO2. *Appl. Environ. Microbiol.* 77, 6755–6762. doi: 10.1128/aem.05116-11

Li, P., Chen, B., Song, Z., Song, Y., Yang, Y., Ma, P., et al. (2012). Bioinformatic analysis of the *Acinetobacter baumannii* phage ABI genome. *Gene* 507, 125–134. doi: 10.1016/j.gene.2012.07.029

Lowe, T. M., and Eddy, S. R. (1997). tRNAscan-SE: a program for improved detection of transfer RNA genes in genomic sequence. *Nucleic Acids Res.* 25, 955–964. doi: 10.1093/nar/25.5.955

Maragakis, L. L., and Perl, T. M. (2008). *Acinetobacter baumannii*: epidemiology, antimicrobial resistance, and treatment options. *Clin. Infect. Dis.* 46, 1254–1263. doi: 10.1086/529198

Mattila, S., Ruotsalainen, P., and Jalasvuori, M. (2015). On-demand isolation of bacteriophages against drug-resistant bacteria for personalized phage therapy. *Front. Microbiol.* 6:1271. doi: 10.3389/fmicb.2015.01271

Nasukawa, T., Uchiyama, J., Taharaguchi, S., Ota, S., Ujihara, T., Matsuzaki, S., et al. (2017). Virus purification by CaCl2 density gradient using general centrifugation. *Arch. Virol.* 162, 3523–3528. doi: 10.1007/s00705-017-3513-z

Nir-Paz, R., Gelman, D., Khouri, A., Sisson, B. M., Fackler, J., Alkalay-Oren, S., et al. (2019). Successful treatment of antibiotic-resistant, poly-microbial bone infection with bacteriophages and antibiotics combination. *Clin. Infect. Dis.* 69, 2015–2018. doi: 10.1093/cid/ciz222

Oliveira, H., Costa, A. R., Ferreira, A., Konstantinides, N., Santos, S. B., Boon, M., et al. (2019). Functional analysis and antivirulence properties of a new depolymerase from a myovirus that infects *Acinetobacter baumannii* capsule K45. *J. Virol.* 93:e01163-18. doi: 10.1128/jvi.01163-18

O’Toole, G. A., and Kolter, R. (1998). Initiation of biofilm formation in *Pseudomonas fluorescens* WCS365 proceeds via multiple, convergent signalling pathways: a genetic analysis. *Mol. Microbiol.* 28, 449–461. doi: 10.1046/j.1365-2958.1998.00797.x

Peleg, A. Y., Seifert, H., and Paterson, D. L. (2008). *Acinetobacter baumannii*: emergence of a successful pathogen. *Clin. Microbiol. Rev.* 21, 538–582. doi: 10.1128/cmr.00058-07

Pereira, S. G., Domingues, V. S., Theriága, J., Chasqueira, M. J., and Paixão, P. (2018). Non-antimicrobial drugs: etodolac as a possible antimicrobial or adjuvant agent against ESKAPE pathogens. *Open Microbiol. J.* 12, 288–296. doi: 10.2174/1874285801812010288

Popova, A. V., Shneider, M. M., Myakina, V. P., Bannov, V. A., Edelstein, M. V., Rubalaki, E. O., et al. (2019). Characterization of myophage AM24 infecting *Acinetobacter baumannii* of the K9 capsular type. *Arch. Virol.* 164, 1493–1497. doi: 10.1007/s00705-019-04208-x

Popova, A. V., Zhilenkov, E. L., Myakina, V. P., Krasilnikova, V. M., and Volozhantsev, N. V. (2012). Isolation and characterization of wide host range lytic bacteriophage AP22 infecting *Acinetobacter baumannii*. *FEMS Microbiol. Lett.* 332, 40–46. doi: 10.1111/j.1574-6968.2012.02573.x

Schooley, R. T., Biswas, B., Gill, J. J., Hernandez-Morales, A., Lancaster, J., Lessor, L., et al. (2017). Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant *Acinetobacter baumannii* Infection. *Antimicrob. Agents Chemother.* 61:e00954-17. doi: 10.1128/aac.00954-17

Verma, V., Harjai, K., and Chhibber, S. (2010). Structural changes induced by a lytic bacteriophage make ciprofloxacin effective against older biofilm of *Klebsiella pneumoniae*. *Biofouling* 26, 729–737. doi: 10.1080/08927014.2010.511196

Yin, S., Huang, G., Zhang, Y., Jiang, B., Yang, Z., Dong, Z., et al. (2017). Phage abp1 rescues human cells and mice from infection by pan-drug resistant *Acinetobacter Baumannii*. *Cell Physiol. Biochem.* 44, 2337–2345. doi: 10.1159/000486117

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Jiang, Tan, Hao, Wang, Yin, Wang, Tuo, Wei and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.